Ministry of Health Proposes Immediate Suspension of Drug Manufacturing Licenses for Non-Compliance

The Ministry of Health and Family Welfare has taken a significant step to fortify the regulatory structure for ensuring the quality and safety of medicines in the country. It has proposed amendments to the Drugs Rules of 1945, aiming to enable the immediate suspension of manufacturing licenses for drugs that do not adhere to specified critical quality standards, classifying them as Not Satisfactory in Quality (NSQ).

The proposed amendments focus on protecting patient safety and public health by facilitating prompt regulatory intervention upon identifying low-quality drugs. This would involve halting their manufacture and distribution while reinforcing the mechanisms to ensure adherence to quality standards.

Under the existing provisions of the Drugs Rules of 1945, a defined regulatory process must be followed before suspension or cancellation of any manufacturing license, which includes issuing a 'show cause notice.' Consequently, there could be a lag between declaring a drug NSQ and initiating regulatory action against it. During this interval, the drug may remain in circulation, posing risks to public health and complicating its recall process.

To address this regulatory concern, the Ministry has proposed a provision allowing the Central Licensing Approval Authority or the State Licensing Authority, as applicable, to suspend the manufacturing license of a drug immediately upon receipt of a government analyst's report, which declares the drug NSQ concerning its testing, disintegration, related substances, impurities, or sterility.

These quality benchmarks are crucial for ascertaining the safety of medicines. The intent of the proposed provision is to ensure that regulatory action occurs swiftly in cases of non-compliance with established standards, thereby minimizing potential threats to patients.

The proposed amendments also mandate that corrective measures must be taken prior to revoking any suspension. This suspension will remain in effect until the manufacturer conducts an effective 'Root Cause Analysis' to identify the reasons for quality failure and satisfactorily implements appropriate Corrective and Preventive Actions (CAPA) to the licensing authority's satisfaction.

The suspension can only be lifted after necessary corrective and preventive measures are applied and subsequently verified by the licensing authority. This process aims to ensure that identified quality deficiencies are adequately addressed and that necessary safeguards are in place to prevent their recurrence in the future.

To strengthen regulatory coordination and streamline timely actions, modifications to the 'Form 13' concerning the government analyst's testing report have also been proposed.

Under the proposed system, the government analyst's report will be disseminated to the Drugs Controller General of India (DCGI), the respective state/union territory licensing authority, and the manufacturers and marketers of the relevant drug.

The objective of this proposed arrangement is to guarantee that findings related to NSQ drugs are promptly communicated to the relevant authorities and stakeholders. This will facilitate coordinated regulatory actions and enhance accountability throughout the drug manufacturing and marketing chain.

The amendments are based on discussions held during the 65th meeting of the Drug Consultative Committee (DCC) on December 20, 2024, and the recommendations from the 92nd meeting of the Drug Technical Advisory Board (DTAB) on April 24, 2025.

These amendments are expected to enhance the monitoring of drugs in the market, facilitate timely actions against substandard medicines, increase accountability among manufacturers and vendors, and bolster public trust in the quality of medicines available in the country.

This initiative reflects the Indian government's ongoing commitment to strengthening the drug regulatory framework and ensuring the availability of safe, effective, and quality medications for the public.

The draft of the amendment has been notified for public consultation, inviting objections and suggestions from stakeholders and the general public. These objections and suggestions can be submitted within 30 days from the date the draft rules become publicly available in the Official Gazette of India.

The draft notification can be viewed on the official e-gazette portal via the following link: https://egazette.gov.in/(S(tqlgzgdze5s0ylovnh4l0ej1))/ViewPDF.aspx